Skip to main content
Show full summary

Lord Mendelsohn to ask Her Majesty's Government, further to the Sars CoV-2 for cancer patients (SOAP) study on the efficacy of COVID-19 vaccines for cancer patients, what plans the Joint Committee on Vaccination and Immunisation has (1) to change, and (2) to apologise for, its statements about (a) the scientific efficacy of the size of study, (b) that study's evaluation of T Cell responses, and (c) that study's lack of consistency of immunological markers, and its conclusion that the study provides no data of relevance for policy recommendations to be made.  HL14929

Question HL14929: tabled on 14 April 2021 and due for answer by 28 April 2021

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

To ask Her Majesty's Government further to the Sars CoV-2 for cancer patients (SOAP) study on the efficacy of COVID-19 vaccines for cancer patients, what plans the Joint Committee on Vaccination and Immunisation has (1) to change, and (2) to apologise for, its statements about (a) the scientific efficacy of the size of study, (b) that study's evaluation of T Cell responses, and (c) that study's lack of consistency of immunological markers, and its conclusion that the study provides no data of relevance for policy recommendations to be made.
Legend for business item text
Item that is new or altered.
[I] Indicates that the member concerned has a relevant registered interest.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.